Fung and the Fox Chase BMT Program receives “Game Changer Award”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Henry Fung and the Fox Chase-Temple University Hospital Bone Marrow Transplant Program willl receive the Andy Talley Bone Marrow Foundation’s first “Game Changer Award” during the 7th Annual Bash March 3.

The Fox Chase-Temple University Hospital BMT Program is one of only three institutions in the country to provide bloodless transplant procedures for patients who request this complex technique. They earned the status of a “Blue Distinction Center for Transplants” by IBC in 2015 in recognition of the Fox Chase-Temple University Hospital Bone Marrow Transplant Program’s expertise in performing adult bone marrow transplants.

The program is fully accredited by the Foundation for the Accreditation of Cellular Therapy—the gold standard of excellence for blood and bone marrow transplant programs in the United States—and the National Marrow Donor Program.

Fung came to Fox Chase from Rush University Medical Center, where he was a professor of medicine since 2005. He served as director of the section of bone marrow transplant and cell therapy; director of the Coleman Foundation Blood and Marrow Transplant Center, where he also held the Coleman endowed chair; clinical leader of hematologic malignancies; and senior attending physician.

Recognition will also be given to Joseph Pawlowski, a Lycoming College Football player who registered as a potential donor at Lycoming Football’s first “Get in the Game, Save A Life” drive in the spring of 2015, was selected as a match, and in November 2015, he had the opportunity to save a football game on Saturday, and a life just four days later. Pawlowski will be recognized, as will the patient who got a second chance, together for the first time in public.

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings. 
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login